Journals / ARTEMİS / 2004 / Cilt: 5 - Sayı: 3

Clinical and metabolic effect of two forms of combined oral contraceptives in women with polycystic ovary syndrome

Polikistik over sendromlu olgularda iki ayrı oral kontraseptif tedavisinin klinik ve metabolik etkileri

Journal
ARTEMİS
Pages
220–223
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However treatment with the cyproterone acetate combi¬ned oral contraceptive is associated with a tendency toward increasing level of triglyceride and total cholesterol.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of the study was to evaluate the effects of cyproterone acetate and desogestrel, as a part of combined oral contraceptives, on hirsutism scores, patients' drug compliance and lipid metabolism of women with polycystic ovary syndrome.
📊
Key Findings & Data:Group I received 0.15 mg desogestrel + 0.02 mg ethinyl estradiol , Group II received 2 mg cyproterone acetate + 0.035 mg ethinylestradiol daily.
💡
Conclusion & Impact:However treatment with the cyproterone acetate combi¬ned oral contraceptive is associated with a tendency toward increasing level of triglyceride and total cholesterol.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of the study was to evaluate the effects of cyproterone acetate and desogestrel, as a part of combined oral contraceptives, on hirsutism scores, patients' drug compliance and lipid metabolism of women with polycystic ovary syndrome. Materials and Methods: Sixteen women complain of hirsutism and diagnosed as polycystic ovary syndrome were admitted study and randomized into two groups. Group I received 0.15 mg desogestrel + 0.02 mg ethinyl estradiol , Group II received 2 mg cyproterone acetate + 0.035 mg ethinylestradiol daily. Hirsutism, serum lipids were measured before and 6 months af¬ter treatments and patient's compliance were evaluated. Results: Treatment with oral contraceptive pills was well tolerated and patients' compliance was similar for two drugs (comp¬liance, 93%, 90%) respectively. No changes in weight, body mass index and waist /hip ratio was observed. While mean tes¬tosterone level and Ferriman Gallwey score was decreased in two groups. Serum LDL and HDL levels increased significantly during therapy. In addition, the difference was not statistically significant between two groups. Although serum triglyceride and total cholesterol level increased in two groups, the increase was higher for Group II. Conclusions: Both combined oral contraceptive formulations are comparably effective in decreasing hirsutism and andro¬gens. In addition, both of treatments had similar impacts on lipids. However treatment with the cyproterone acetate combi¬ned oral contraceptive is associated with a tendency toward increasing level of triglyceride and total cholesterol.

Özet

Amaç: Bu çalışmada, siproteron asetat ve desogestrel gibi iki ayrı progesteron içeren kombine oral kontraseptiflerin hasta uyumu, hirsutizm skoru ve lipid metabolizması üzerine etkilerinin araştırılması amaçlandı. Materyal ve Metot: Kıllanma yakınmasıyla kliniğe başvuran ve polikistik over sendrom tanısı alan 60 olgu çalışma kapsamına alındı ve olgular randomize edilerek iki gruba ayrıldı. Birinci gruba 0.15 mg desogestrel+0.02 mg etinil östradiol içeren, ikinci gruba 2 mg siproteron asetat+0.035 mg etinil östradiol içeren düşük doz kombine oral kontraseptif başlandı. Olguların tedavi öncesi ve 6 ay sonraki ilaç uyumu, hirsutizm skorları ve kan lipid düzeyleri değerlendirildi ve farklılıklar istatistiksel olarak analiz edildi. Sonuçlar: Her iki ilaç hastalar tarafından iyi tolere edildi ve Grup I için hasta uyumu %93 iken, Grup II için %90 idi. Olguların altı aylık tedavi sonucunda kilo, bel/kalça oranı ve vücut kitle indekslerinde bir değişim olmadığı saptandı. Serum testosteron düzeyi ve Ferriman Gallwey hirsutizm skorunun 6 aylık tedavi sonrası her iki grupta benzer oranda düştüğü gözlendi. Her iki grupta da serum LDL ve HDL düzeyi tedavi sonrası benzer oranda yükseldi. Serum TG ve total kolesterol oranı her iki grupta da yükselirken yükselmenin Grup II olgularda Grup I olgulara göre daha fazla olduğu saptandı. Tartışma: Her iki oral kontraseptif formülü hirsutizm skoru üzerine benzer etki yaparken, serum lipidleri üzerine de benzer etki gösterebilmektedir. Ama her iki grupta da TG ve total kolesterol yükselirken, yükselmenin siproteron asetat içeren grupta daha fazla olabileceği akılda tutulmalıdır.

🔖

Cite This Article

TOK, E., ARSLAN, M., DİLEK, S., ÇAMDEVİREN, H., ÇİL, F., PATA, Ö., DİLEK, U. (2022). Clinical and metabolic effect of two forms of combined oral contraceptives in women with polycystic ovary syndrome. ARTEMİS, Cilt: 5 - Sayı: 3, 220–223. https://ajindex.com/articles/449483

References (13)

  1. Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf). 1989;31(1 ):87-120
  2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9):3078-82
  3. Speroff L, Glass RH, Kase NG (ed). Anovulation and polycystic ovary. In Clinical Gynecologic Endocrinology and Infertility. Ilustration and page design by Lisa Million. Lippincott Williams and Wilkins. Baltimore, Maylard USA 1999; pp487
  4. Nestler JE. Long term impact of androgen excess. Androgen excess disorders in women. Edited by R Azziz, J.E. Nestler, and D.Dewailly. Lippincott-Raven Publishers, Philadelphia 1997:pp 667-705
  5. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am. 200l;28(l):l 11-33
  6. Legro LS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 1999;84; 165-69
  7. Crook D, Godsland I. Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism. Contraception. 1998;57(3): 189-201
  8. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subtractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf). 2001;54(4):447-53
  9. Dahlgren E, Landin K. Krotkiewski M, Holm G, Janson PO. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod. 1998;13(10):2706-11
  10. Cibula D, Hill M, Fanta M, Sindelka G, Zivny J. Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome? Hum Reprod. 2001;16(5):940-4
  11. Creatsas G, Koliopoulos C, Mastorakos G. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile Ann N Y Acad Sci. 2000;900:245-52
  12. Dewis P, Petsos P, Newman M, Anderson DC. The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol.Clin Endocrinol (Oxf). 1985;22(l):29-36
  13. Speroff L, Glass RH, Kase NG (Ed). Hirsutism. In Clinical Gynecologic Endocrinology a